Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CureVac N.V. (CVAC : NSDQ)

• Company Description    CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany. Number of Employees: 983

• Price / Volume Information    Yesterday's Closing Price: $5.46 Daily Weekly Monthly 20 Day Moving Average: 1,088,946 shares Shares Outstanding: 224.34 (millions) Market Capitalization: $1,224.89 (millions) Beta: 2.53 52 Week High: $5.72 52 Week Low: $2.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.50% -5.84% 12 Week 75.00% 47.69% Year To Date 60.12% 49.67%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Friedrich-Miescher-Strasse 15 - Tubingen,2M 72076 DEU ph: 49-70-71988-30 fax: 49-7071-9883 investors@curevac.com http://www.curevac.com

• General Corporate Information    Officers Alexander Zehnder - Chief Executive Officer Baron Jean Stephenne - Chairman and Director Malte Greune - Chief Operating Officer Axel Sven Malkomes - Chief Financial Officer Craig A. Tooman - Director Peer Information CureVac N.V. (CORR.) CureVac N.V. (RSPI) CureVac N.V. (CGXP) CureVac N.V. (BGEN) CureVac N.V. (GTBP) CureVac N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N2451R105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/21/25 Share - Related Items Shares Outstanding: 224.34 Most Recent Split Date: (:1) Beta: 2.53 Market Capitalization: $1,224.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.51 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 19.31% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/21/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 5.93 PEG Ratio: - Price Ratios Price/Book: 1.80 Price/Cash Flow: 6.25 Price / Sales: 2.13 EPS Growth vs. Year Ago Period: 29.41% vs. Previous Quarter: -60.00% Sales Growth vs. Year Ago Period: -93.01% vs. Previous Quarter: -93.92% ROE 06/30/25 - - 03/31/25 - 30.89 12/31/24 - 29.79 ROA 06/30/25 - - 03/31/25 - 25.54 12/31/24 - 23.04 Current Ratio 06/30/25 - - 03/31/25 - 7.65 12/31/24 - 7.28 Quick Ratio 06/30/25 - - 03/31/25 - 7.64 12/31/24 - 7.27 Operating Margin 06/30/25 - - 03/31/25 - 35.44 12/31/24 - 30.97 Net Margin 06/30/25 - - 03/31/25 - 35.44 12/31/24 - 30.97 Pre-Tax Margin 06/30/25 - - 03/31/25 - 39.67 12/31/24 - 35.67 Book Value 06/30/25 - - 03/31/25 - 3.04 12/31/24 - 3.36 Inventory Turnover 06/30/25 - - 03/31/25 - 129.72 12/31/24 - 15.24 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.05 12/31/24 - 0.05 Debt-to-Capital 06/30/25 - - 03/31/25 - 4.74 12/31/24 - 4.61

Powered by Zacks Investment Research ©